FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2600151991> ?p ?o ?g. }

• W2600151991 abstract "420 Background: Advanced biliary cancers respond poorly to chemotherapy and have a dismal survival. Currently gemcitabine-cisplatin (GC) is the standard of care for patients with advanced disease. The efficacy of second line treatment options is not well-defined. We retrospectively evaluated outcomes of patients undergoing second line treatment for advanced biliary cancers at Mayo Clinic. Methods: After obtaining approval from the institutional board review (IRB), we identified 42 patients with advanced and metastatic biliary cancers that progressed after first line (GC) and received second line treatment from 2007-2014. All patients had adequate follow up data. JMP software was used for statistical analysis. Kaplan-Meier method and log-rank tests were used for survival analysis, and multivariate cox proportional hazards model was used to evaluate the prognostic effect of pertinent clinical variables. All tests were two sided and a P value of < 0.05 was considered significant. Results: The median age at diagnosis was 61.5 (range 26-87). The most common regimens used for second line settings were 5-FU-based (69%) followed by gemcitabine-based regimens (19%). The overall response rate (ORR) was 9.1%, while the disease control rate (DCR; stable disease and partial response) was 33%. The median overall survival (mOS) for the entire cohort from first line was 16.8 months (95% CI 12.7-21.7) and the progression-free survival (PFS) was 9.16 months (95% CI 7.3-14.7). From second line start the mOS was 10.4 months (95%; CI 7.3-23.7), and PFS was 2.8 months (95% CI 2.3-4.0). 73% of patients who received second line therapy were alive at 6 months and 50% at 12 months. 25 patients received third line treatment after progression. An univariate and multivariate analysis were performed including age, sex, stage at diagnosis, regimen used, CA19-9 and total body weight loss > 5%, but no significant prognostic factors were identified. Conclusions: Patients with biliary cancers who progress after first line treatment have poor prognosis, but may benefit from second line regimens. 5-FU based regimens were the most commonly used in the second line setting, and 73% of patients who received second line therapy were alive at 6 months." @default.
• W2600151991 created "2017-04-07" @default.
• W2600151991 creator A5015599437 @default.
• W2600151991 creator A5018405630 @default.
• W2600151991 creator A5019214686 @default.
• W2600151991 creator A5033205656 @default.
• W2600151991 creator A5039231090 @default.
• W2600151991 creator A5041487489 @default.
• W2600151991 creator A5043192225 @default.
• W2600151991 creator A5044158125 @default.
• W2600151991 creator A5090608376 @default.
• W2600151991 date "2017-02-01" @default.
• W2600151991 modified "2023-10-06" @default.
• W2600151991 title "Outcomes of second line treatment in patients with advanced and metastatic biliary cancers." @default.
• W2600151991 doi "https://doi.org/10.1200/jco.2017.35.4_suppl.420" @default.
• W2600151991 hasPublicationYear "2017" @default.
• W2600151991 type Work @default.
• W2600151991 sameAs 2600151991 @default.
• W2600151991 citedByCount "0" @default.
• W2600151991 crossrefType "journal-article" @default.
• W2600151991 hasAuthorship W2600151991A5015599437 @default.
• W2600151991 hasAuthorship W2600151991A5018405630 @default.
• W2600151991 hasAuthorship W2600151991A5019214686 @default.
• W2600151991 hasAuthorship W2600151991A5033205656 @default.
• W2600151991 hasAuthorship W2600151991A5039231090 @default.
• W2600151991 hasAuthorship W2600151991A5041487489 @default.
• W2600151991 hasAuthorship W2600151991A5043192225 @default.
• W2600151991 hasAuthorship W2600151991A5044158125 @default.
• W2600151991 hasAuthorship W2600151991A5090608376 @default.
• W2600151991 hasConcept C10515644 @default.
• W2600151991 hasConcept C126322002 @default.
• W2600151991 hasConcept C143998085 @default.
• W2600151991 hasConcept C2776694085 @default.
• W2600151991 hasConcept C2780258809 @default.
• W2600151991 hasConcept C3018840467 @default.
• W2600151991 hasConcept C38180746 @default.
• W2600151991 hasConcept C50382708 @default.
• W2600151991 hasConcept C71924100 @default.
• W2600151991 hasConceptScore W2600151991C10515644 @default.
• W2600151991 hasConceptScore W2600151991C126322002 @default.
• W2600151991 hasConceptScore W2600151991C143998085 @default.
• W2600151991 hasConceptScore W2600151991C2776694085 @default.
• W2600151991 hasConceptScore W2600151991C2780258809 @default.
• W2600151991 hasConceptScore W2600151991C3018840467 @default.
• W2600151991 hasConceptScore W2600151991C38180746 @default.
• W2600151991 hasConceptScore W2600151991C50382708 @default.
• W2600151991 hasConceptScore W2600151991C71924100 @default.
• W2600151991 hasLocation W26001519911 @default.
• W2600151991 hasOpenAccess W2600151991 @default.
• W2600151991 hasPrimaryLocation W26001519911 @default.
• W2600151991 isParatext "false" @default.
• W2600151991 isRetracted "false" @default.
• W2600151991 magId "2600151991" @default.
• W2600151991 workType "article" @default.